GlassScriptPhysician profile
Bonny Bautista
NPI 1245807783
$2,071.42
in general payments reported to CMS, 2019-2025
26 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $42.17 · 2023: $51.74 · 2024: $434 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,929.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $342.80 | 2022-2025 | |
| Novo Nordisk INC | $273.15 | 2024-2025 | Wegovy, Ozempic |
| Exact Sciences Corporation | $147.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $141.09 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $138.93 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $100.00 | 2021 | |
| Glaxosmithkline, LLC. | $97.95 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Verona Pharma, INC. | $94.95 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $81.37 | 2024-2025 | Voquezna |
| Abiomed | $80.81 | 2025 | |
| Amgen INC. | $78.30 | 2024-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $70.19 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $64.21 | 2024-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.42 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $35.54 | 2025 | Capvaxive, Gardasil 9 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $35.00 | 2025 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.91 | 2024-2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $33.66 | 2025 | Gvoke Hypopen |
| Sequel Med Tech, LLC | $32.82 | 2025 | Twiist |
| Pfizer INC. | $29.40 | 2025 | |
| Corcept Therapeutics | $27.44 | 2025 | Korlym |
| Stryker Corporation | $22.49 | 2025 | Clottriever Bold Catheter |
| Kowa Pharmaceuticals America, INC. | $19.57 | 2025 | Zoryve |
| Irhythm Technologies, INC. | $18.87 | 2023 | Zio Xt Patch |
| Kyowa Kirin, INC. | $16.32 | 2025 | |
| Esperion Therapeutics, INC. | $14.96 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bonny Bautista listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.